Table 2.
Base case analysis–results–costs per patient and cost-utility analysis (€2020).
| Items | STN1013001 (%) | Latanoprost (%) | Difference (%) [95% CI]a,b |
|---|---|---|---|
| French health system viewpoint | |||
| Cost | |||
| Diagnosis | €191.60 (8.16) | €192.75 (8.24) | −€1.15 (14.63) [−€32.62; €30.80] |
| Medications | €341.28 (14.54) | €241.81 (10.33) | €99.47 (−1070.48) [€95.04; €104.53] |
| Add-on therapies and follow-up | €1337.59 (56.97) | €1339.40 (57.23) | −€1.81 (22.14) [−€146.76; €143.26] |
| OSD management | €477.27 (20.33) | €566.38 (24.20) | −€89.11 (1133.72) [−€160.16; −€19.73] |
| Overall | €2347.74 (100.00) | €2340.34 (100.00) | €7.39 (100) [−€159.39; €166.60] |
|
| |||
| LYS and QALYs | |||
| LYS | 4.228 | 4.223 | 0.005 [−0.013; 0.023] |
| QALYs | 2.539 | 2.191 | 0.348 [0.285; 0.408] |
|
| |||
| Cost-utility analysis | |||
| Incremental costs (ΔC) | €7.39 | ||
| Incremental QALYs (ΔQALYs) | 0.348 | ||
| ICUR (ΔC/ΔQALYs) | €21.26 | ||
a(STN1013001–Latanoprost). b95% CI was calculated via the percentile method [34]. CI = confidence interval; ICUR = incremental cost-utility ratio; LYS = life year saved; OAG/OHT = open-angle glaucoma/ocular hypertension; OSD = ocular surface disease; and QALYs = quality-adjusted life years. Bold fonts were used to highlight some results.